SAN DIEGO--(BUSINESS WIRE)--Mar. 28, 2018--
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage
biotechnology company focused on improving the lives of patients by
developing best-in-class treatments to address some of the most
important unmet patient needs, today announced that it intends to offer
and sell shares of its common stock in an underwritten registered public
offering. All of the shares in the offering are to be sold by Heron
Therapeutics, Inc. The offering is subject to market conditions, and
there can be no assurance as to whether or when the offering may be
completed, or the actual size or terms of the offering.
Heron Therapeutics, Inc. intends to use the net proceeds from the
underwritten offering for the commercial launch of HTX-011, if approved
by the U.S. Food and Drug Administration, the continued
commercialization and marketing of SUSTOL® and CINVANTI®,
the company’s ongoing and future clinical trials, including further
clinical studies for HTX-011, preclinical development work, other
product development activities and general corporate purposes.
Jefferies, Cowen and Evercore ISI are acting as joint book-running
managers for the offering; Cantor and JMP Securities are acting as lead
managers for the offering; and LifeSci Capital, Lake Street Capital
Markets, National Securities Corporation, Noble Capital Markets and
Northland Capital Markets are each acting as co-managers for the
offering. Heron Therapeutics, Inc. intends to grant the underwriters a
30-day option to purchase up to an additional 15% of the shares of
common stock sold in the public offering.
A registration statement relating to these securities has been filed
with the Securities and Exchange Commission and became automatically
effective on July 6, 2017.
A preliminary prospectus supplement and accompanying base prospectus
relating to and describing the terms of the offering will be filed with
the SEC. The securities described above have not been qualified under
any state blue sky laws. This press release shall not constitute an
offer to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of
any such state or other jurisdiction. The offering can be made only by
means of a prospectus, copies of which may be obtained at the SEC’s
website at www.sec.gov,
or by request at Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by
telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com;
Cowen and Company, LLC c/o Broadridge Financial Services, 1155 Long
Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or
by phone at (631) 274-2806; or Evercore Group L.L.C. at Attention Equity
Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by
telephone at (888)474-0200, or by email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
jurisdiction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180328006134/en/
Source: Heron Therapeutics, Inc.
Investor Relations Contact:
David Szekeres, 858-251-4447
Senior
Vice President, General Counsel, Business Development & Corporate
Secretary
dszekeres@herontx.com
or
Corporate
Contact:
David Szekeres, 858-251-4447
Senior Vice
President, General Counsel, Business Development & Corporate Secretary
dszekeres@herontx.com